These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31396919)

  • 41. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
    Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
    HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.
    Puenpatom A; Hull M; McPheeters J; Schwebke K
    Clin Drug Investig; 2017 Jul; 37(7):687-697. PubMed ID: 28386819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals.
    Seko Y; Moriguchi M; Takahashi A; Okishio S; Kataoka S; Okuda K; Mizuno N; Takemura M; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
    Intern Med; 2020; 59(15):1811-1817. PubMed ID: 32741890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacology Update for the Treatment of Hepatitis C Virus.
    Hopkins L; Dunlap T; Cline H
    Nurs Clin North Am; 2020 Sep; 55(3):347-359. PubMed ID: 32762855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.
    Kyvernitakis A; Mahale P; Popat UR; Jiang Y; Hosry J; Champlin RE; Torres HA
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):717-722. PubMed ID: 26712592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    Gupta N; Kabahizi J; Mukabatsinda C; Walker TD; Musabeyezu E; Kiromera A; Van Nuil JI; Steiner K; Mukherjee J; Nsanzimana S; Mbituyumuremyi A
    PLoS One; 2017; 12(3):e0174148. PubMed ID: 28323868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study.
    Boglione L; Mornese Pinna S; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
    J Viral Hepat; 2017 Oct; 24(10):850-857. PubMed ID: 28345206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
    Lin SF; Tung SY; Wei KL; Chen CH; Hu TH; Shen CH; Chang TS; Chen WM; Yen CW; Wang JH; Hung CH; Lu SN
    PLoS One; 2020; 15(3):e0229994. PubMed ID: 32126125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
    Honma Y; Shibata M; Hayashi T; Kusanaga M; Ogino N; Minami S; Kumei S; Oe S; Miyagawa K; Senju M; Matsuoka H; Watanabe T; Hiura M; Abe S; Harada M
    Liver Int; 2019 Sep; 39(9):1641-1651. PubMed ID: 31009141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
    Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
    J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Investigation of the Side Effects, Patient Feedback, and Physiological Changes Associated with Direct-Acting Antiviral Therapy for Hepatitis C.
    Wu PS; Chang TS; Lu SN; Su HJ; Chang SZ; Hsu CW; Chen MY
    Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31817863
    [No Abstract]   [Full Text] [Related]  

  • 55. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
    Sidharthan S; Kohli A; Sims Z; Nelson A; Osinusi A; Masur H; Kottilil S
    Clin Infect Dis; 2015 Jun; 60(12):1743-51. PubMed ID: 25733369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Optimal antiviral therapy of chronic hepatitis caused by hepatitis C virus].
    Cooreman MP; Stadhouders P
    Orv Hetil; 1997 Jun; 138(22 Suppl 1):1476-82. PubMed ID: 9221377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.
    Guardigni V; Cento V; Ianniruberto S; Badia L; Aragri M; Conti M; Perno CF; Viale P; Ceccherini-Silberstein F; Verucchi G
    Infection; 2018 Oct; 46(5):717-720. PubMed ID: 29804205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of Post-Liver Transplant Recurrence of Hepatitis C.
    Taylor J; Cox-North P; Landis CS
    Drugs; 2016 Dec; 76(18):1711-1717. PubMed ID: 27878476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.